Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Lancet 2:13001304 Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [736 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
With obesity on the rise, drugs like Ozempic and Mounjaro, both designed for people with Type 2 diabetes, have surged in popularity over the past year, as they can help people lose weight
Adherence rates for oral formulations are typically 5-10% lower than injectables due to administration complexity and GI side effects (nausea, constipation, diarrhea)
LDL, lowdensity lipoprotein
Unlike older weight loss medications that primarily suppress appetite, tirzepatide and Ozempic help with weight loss by influencing multiple biological processes, including digestion, hunger signals, and fat metabolism
US$ 28.89
US$ 21.65
US$ 25.17
US$ 22.03
US$ 22.14
